Rho GTPase activating protein 18Genealiases: MacGAP · SENEX · bA307O14.2
Q-omics provides the consensus-scored ARHGAP18 profile across patient tissues and cancer cell-line models. ARHGAP18 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ARHGAP18 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, ARHGAP18 protein abundance shows 27,305 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, LUSC, and LSCC as cancer lineages where ARHGAP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP18 survival associations across molecular data types. ARHGAP18 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP18 RNA expression–survival associations across cancer types. High ARHGAP18 expression shows unfavorable associations in LGG, UVM and LUSC, but favorable associations in SKCM, KIRC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ARHGAP18 RNA expression.
This table summarizes ARHGAP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP18 shows lower tumor expression in LUSC, LUAD, KIRP and KIRC and higher tumor expression in LIHC and STAD. The LUSC box plot shows higher ARHGAP18 RNA expression in normal versus tumor tissue (log2 FC = −2.381, t-test p < 0.001).
This table shows molecular features associated with ARHGAP18 in patient tissues and cancer cell lines. In patient samples, ARHGAP18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
